Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPENAL)

Drug Name

FSI-189 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-hodgkin lymphoma	2B33.5	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Inhibitory receptor SHPS-1 (SIRPA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CC-95251	DM7E1W0	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
BI 765063	DMZMAOW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Inhibitory receptor SHPS-1 (SIRPA)	TTBRJS9	SHPS1_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04502706) Study of FSI-189 as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
2	T cells bring unconventional cancer-targeting to the clinic - again. Nat Biotechnol. 2020 Apr;38(4):389-391.
3	ClinicalTrials.gov (NCT03783403) A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPalpha, in Subjects With Advanced Solid and Hematologic Cancers. U.S. National Institutes of Health.
4	Clinical pipeline report, company report or official report of OSE Immunotherapeutics.